NLRP3 and autoimmune disease: On the other hand, the emerging role of TLR4 and NLRP3 activation in inflammatory and autoimmune diseases, such as sepsis and lupus, among others has suggested the use of TLR4 and NLRP3 antagonists in therapy [41–45].